Alpha-Linolenic acid
|
Basic information |
| Metabolite name | Alpha-Linolenic acid |
 | HMDB0001388 |
 |
C06427 |
 |
5280934 |
| Synonyms | 9,12,15-Octadecadienoic acid; |
| No. of studies | 19 |
|
Basic information |
| Metabolite name | Alpha-Linolenic acid |
| HMDB0001388 |
|
C06427 |
|
5280934 |
| Synonyms | 9,12,15-Octadecadienoic acid; |
| No. of studies | 19 |
|
Relationship between Alpha-Linolenic acid and depression (count: 19) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M1010 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA3 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | DG region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA1 region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA3 region of hippocampus | ICR mouse | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Up |
| Study M1090 | Type1 | CUMS group vs. control group | Plasma | BALb/c mouse | Down |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1097 | Type2 | probiotic-treated depression group vs. placebo-treated depression group | Faece | Human | Down |
| Study M1103 | Type1 | SLE with depression group vs. control group | Faece | Human | Up |
| Study M1111 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1111 | Type1 | CUMS group vs. control group | Plasma | C57BL/6 mouse | Down |
| Study M1111 | Type3 | rTMS group vs. control group | Plasma | C57BL/6 mouse | Down |
| Study M1142 | Type2 | MDD group, after intermittent theta burst stimulation vs. baseline | Plasma | Human | Down |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Down |
| Study M464 | Type1 | drug-naive MDD group vs. control group | Plasma | Human | Down |
| Study M487 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M512 | Type1 | CUMS group vs. control group | Plasma | Goto-Kakizaki rat | Down |
| Study M547 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M582 | Type1 | CUMS group vs. control group | Faece | C57BL/6N mouse | Up |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Up |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |